A Novel Mobile App & Population Management System to Manage Rheumatoid Arthritis Flares
Arthritis, Rheumatoid Arthritis
About this trial
This is an interventional supportive care trial for Arthritis focused on measuring Rheumatoid Arthritis, Mobile Health, Pain, Arthritis
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of RA by a board-certified rheumatologist
- Taking a DMARD (sulfasalazine, methotrexate, leflunomide, azathioprine, certolizumab, cyclosporine, adalimumab, etanercept, infliximab, golimumab, abatacept, tocilizumab, anakinra, tofacitinib, rituximab, hydroxychloroquine)
- Own a smart phone with either an Android or iPhone operating system
- Be English-speaking
Exclusion Criteria:
- Patients who do not plan on receiving follow-up care at the Brigham and Women's Hospital Arthritis Center
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Mobile Application + Population Manager
No Mobile Application
This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.